Guide for Authors

  • All journal information and instructions compiled in one document (PDF) in just one mouse-click Author information pack

    INTRODUCTION
    • Types of submissions
    • Pre-submission enquiries 
    BEFORE YOU BEGIN
    • Ethics in publishing
    • Conflict of interest
    • Submission declaration and verification
    • Authorship
    • Changes to authorship
    • Reporting clinical trials
    • Copyright
    • Role of the funding source
    • Funding Body Agreements and Policies
    • Open access (OA)
    • Language (usage and editing services)
    • Submission
    PREPARATION
    • Article structure
    • Essential Title Page Information
    • Abstract
    • Keywords
    • Graphical abstract
    • Highlights
    • Acknowledgements
    • Conflict of Interest
    • Units
    • Math formulae
    • Artwork
    • Illustration services
    • Tables
    • References
    • Video data
    • AudioSlides
    • Submission Checklist
    AFTER ACCEPTANCE
    • Use of the Digital Object Identifier
    • Proofs
    • Offprints
    AUTHOR INQUIRIES



    Current Therapeutic Research serves an international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings by quickly disseminating research findings. The journal provides a home for the rapid publication of:
    •Original reports of recent developments in drug therapy, including papers presenting unexpected, controversial, provocative and/or negative results
    •Research letters, presenting research that may stimulate further investigation or alert readers to clinically relevant but preliminary findings
    •In-depth review articles on specific drug therapies or disease states
    •Applied health economics papers, aimed at a clinical audience
    •Trials From Resource-Limited Settings intended to highlight original medical and pharmaceutical reports from resource-limited settings

    CTR is a peer-reviewed, author pays, online journal, and the final published article will be universally accessible on all of Elsevier's platforms. In addition, the articles are indexed by all major biomedical abstracting databases.

    Types of submissions

    Published articles range from studies exploring new drugs and new indications for existing drugs to large, multicenter Phase III and IV trials. The journal also encourages submission of brief reports and commentaries on topics that are timely or provocative. For further information, click on the links below:

    Original Research
    http://cdn.elsevier.com/promis_misc/ctr_original%20research.pdf

    Review Articles and Meta-analyses
    http://cdn.elsevier.com/promis_misc/ctr_review%20articles%20and%20meta-analyses.pdf

    Commentaries
    http://cdn.elsevier.com/promis_misc/ctr_commentaries.pdf

    Brief Reports
    http://cdn.elsevier.com/promis_misc/ctr_brief%20reports.pdf

    Research Letters
    http://cdn.elsevier.com/promis_misc/ctr_research%20letters.pdf

    Letters to the Editor
    http://cdn.elsevier.com/promis_misc/ctr_letters%20to%20the%20editor.pdf

    All manuscripts are peer reviewed by at least 2 independent researchers for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a double-blind review process.

    Pre-submission enquiries 

    Current Therapeutic Research is delighted to respond to pre-submission enquiries and recommends prior contact where publication is desired by a certain date. Please contact the editorial office at currtherres@elsevier.com; all queries will be dealt with promptly.

    Ethics in publishing

    For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

    The work described in your article must have been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.htmlEC Directive 86/609/EEC for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htmUniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This must be stated at an appropriate point in the article.

    Prospective, Observational, or Interventional Pre- and Post-marketing Studies
    Pre- or post-marketing studies must undergo review by an institutional review board (IRB) or ethics committee. Patients must give written informed consent unless a waiver of consent is allowed by the IRB. Patients must be informed of any real or potential conflicts of interest, including compensation of the investigator and potential costs to the patient that may result from their participation in the study. The amount of the remuneration of the investigators for their participation in pre- or post-marketing studies must be approved by the IRB/ethics committee. If the design of a prospective pre- or post-marketing study calls for a treatment intervention such as a switch or withdrawal, then criteria must be established a priori for patient selection, the implementation of the intervention, and assessment of success/failure of such intervention. Such criteria must be scientifically justified, documented, uniformly applied and enforced, and clearly reported in the study report. Additionally, the patient or his/her insurance provider will not be required to pay for costs related to prospective interventions, such as those that may result from a drug switch or withdrawal.

    All other studies that involve identifiable human subjects, including retrospective studies, chart reviews, post-marketing surveillance studies, or government mandated phase IV trials require IRB or ethics committee approval or waiver.

    In each case, detailed IRB or ethics committee information should be clearly stated in the Methods section.

    Studies that only utilize pre-existing, de-identified (according to HIPAA standards) patient data are not required to seek IRB approval.

    Conflict of interest

    All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

    Submission declaration and verification

    Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck http://www.elsevier.com/editors/plagdetect.

    Authorship

    All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

    Changes to authorship

    This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
    Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the editorial office from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Note that publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
    After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in an erratum.

    Reporting clinical trials

    All randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. This journal has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioral treatments, dietary interventions including vitamin or herbal supplements, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. Further information can be found at http://www.icmje.org.

    Studies that were initiated without registration can be registered retrospectively and will be considered for publication on a subjective basis.

    Copyright

    Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' where authors will retain copyright (for more information on this see http://www.elsevier.com/OAauthoragreement). Permitted reuse of open access articles is determined by the author's choice of user license (see http://www.elsevier.com/openaccesslicenses).

    Retained author rights
    As an author you (or your employer or institution) retain certain rights, including copyright; for details you are referred to http://www.elsevier.com/OAauthoragreement.

    Role of the funding source

    You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

    Funding Body Agreements and Policies

    Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

    Open access (OA)

    This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

    Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

    Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

    If you need to comply with your funding body policy you can apply for a CC-BY license after your manuscript is accepted for publication.

    To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders.

    The ability to pay the fee does not influence decisions regarding the acceptance of a paper, which is solely dependent on the peer-review process.

    Elsevier has established agreements with funding bodies, including Wellcome Trust and Research Councils UK. This ensures authors can comply with funding body Open Access policies and may also be reimbursed for their publication fees.

    Payment of Author Fees
    Authors will receive payment instructions once their article is accepted. Contact the Journal Editorial Office (currtherres@elsevier.com) for all queries.

    Fee Waiver Policy
    At the discretion of the Publisher, authors living in one of the HINARI eligible countries and/or belonging to one of the participating institutions may be granted discounts or complete fee waivers. Please visit the following sites for further information on HINARI:

    On Elsevier.com http://www.elsevier.com/wps/find/intro.cws_home/philanthropy

    Link to HINARI http://www.who.int/hinari/en/

    Some universities have signed the Compact for Open-Access Publishing Equity (COPE): "the timely establishment of durable mechanisms for underwriting reasonable publication charges for articles written by its faculty and published in fee-based open-access journals and for which other institutions would not be expected to provide funds." More information about COPE and the list of signatories can be found at http://www.oacompact.org. A list of institutions that provide funding for Open Access can be found at http://www.arl.org/sparc/bm~doc/oa-funds-in-action-attachment.pdf.

    No fee waiver will be granted after a manuscript is submitted.

    The open access publication fee for this journal is $1200, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

    Language (usage and editing services)

    Please write your text in standard, grammatically correct English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop http://webshop.elsevier.com/languageediting/ or visit our customer support site http://support.elsevier.com for more information.

    Submission

    Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail, removing the need for a paper trail.

    Submit your article
    Please submit your article via http://ees.elsevier.com/curtherres.

    Online Publication
    Fully typeset, copyedited and citable versions of all accepted articles are typically published online 25 business days after payment of the Open Access fee is received (subject to prompt turnaround of proof by author).

    Additional information
    Drugs should be referred to by their universally accepted generic names, not by company trademarks. US adopted names (USANs) are acceptable. If unnamed compounds are referred to, as much information as possible (e.g., class of compound) should be included and published references to the compound should be provided. If this is not possible because of intellectual property reasons then this should be stated.

    Footnotes and uncommon abbreviations should be avoided whenever possible. When abbreviations or symbols are used, they should be defined in the text the first time they appear as well as in the tables and figures.

    Any material that has been published elsewhere must be accompanied by written consent from the original author and publisher for print and electronic reproduction.

    Article structure

    Essential Title Page Information

    Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
    Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a superscript Arabic numeral immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
    Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.
    Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

    Abstract

    A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations. The following abstract headings should be used: Background, Objectives, Methods, Results, and Conclusions.

    Keywords

    Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

    Introduction
    State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

    Material and methods
    Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

    Results
    Results should be clear and concise.

    Discussion
    This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

    Conclusions
    The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

    Graphical abstract

    A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.
    Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: Illustration Service.

    Highlights

    Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See http://www.elsevier.com/highlights for examples.

    Acknowledgements

    Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

    Conflict of Interest

    At the end of the text and preceding the references section, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. As a guideline see the ICMJE form for disclosure of Potential Conflicts of Interest at: http://www.icmje.org/coi_disclosure.pdf In order to maintain the double blind peer review process, we recommend that first and last initials are used in place of author names within this section.

    Units

    Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

    Math formulae

    Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

    Artwork

    Electronic Artwork
    General points
    • Make sure you use uniform lettering and sizing of your original artwork.
    • Embed the used fonts if the application provides that option.
    • Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
    • Number the illustrations according to their sequence in the text.
    • Use a logical naming convention for your artwork files.
    • Provide captions to illustrations separately.
    • Submit each illustration as a separate file.
    A detailed guide on electronic artwork is available on our website:
    http://www.elsevier.com/artworkinstructions
    You are urged to visit this site; some excerpts from the detailed information are given here.
    Formats
    If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
    Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
    EPS (or PDF): Vector drawings, embed all used fonts.
    TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
    TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
    TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
    Please do not:
    • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
    • Supply files that are too low in resolution;
    • Submit graphics that are disproportionately large for the content.

    Illustration services

    Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

    Figure captions
    Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

    Tables

    Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with the following symbols, in order: *, †, ‡, §, ∥, ¶, **, ††, etc. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

    References

    Citation in Text
    Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Personal communications should not be included in the reference list, but in the text immediately following the referenced material. Citation of a reference as "in press" implies that the item has been accepted for publication.

    Unless there are compelling reasons to do so, which should be clearly communicated to the editor, "data on file," "internal reports," material that has been "submitted for publication," and related non-peer-review sources are prohibited. Likewise, meeting abstract data, even if published, should be avoided.

    Package inserts are not valid data sources unless in reference to prescribing information such as dosing. All other drug information should be derived from the primary literature and cited accordingly.

    Reference formatting
    There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

    Web References
    As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given.

    Journal abbreviations source
    Journal names should be abbreviated according to the List of Title Word Abbreviations: http://www.issn.org/services/online-services/access-to-the-ltwa/.

    Video data

    Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions.

    AudioSlides

    The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

    Submission Checklist

    The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.
    Ensure that the following items are present:

    Cover letter
    •Title, authors, number of pages, and numbers of tables and figures
    •Indication that the paper has been read and approved by all authors
    •Description of how each author contributed to the manuscript and others who may have assisted
    •Name of the Special Section in which the paper is to be included, if applicable
    •Information about any previous presentation of the data (eg, at a specific meeting)
    •Information about the existence of any closely related manuscripts that have been submitted for simultaneous consideration to the same or another journal
    •Notice of any interests that might be seen as influencing the research (eg, financial interest in a test or procedure, funding by pharmaceutical companies for drug research, etc)
    •A copy of the permission granted to reproduce or adapt any copyrighted material from another source or a notice that permissions are pending

    Title page
    •Full title
    •All authors listed with academic degrees and affiliations
    •One author designated as Corresponding Author:
    •E-mail address
    •Full postal address
    •Telephone and fax numbers
    •Keywords

    Manuscript
    All figure legends (if applicable)
    All figures (if applicable) uploaded individually
    All tables (including title, description, footnotes) uploaded individually

    Further considerations
    •Manuscript has been 'spell-checked' and 'grammar-checked'
    •References are in the correct format for this journal
    •All references mentioned in the reference list are cited in the text, and vice versa
    •Permission has been obtained for use of copyrighted material from other sources (including the Web)

    For any further information, please visit our customer support site at http://support.elsevier.com.

    Failure to comply with any or all of these guidelines could result in rejection of an otherwise acceptable paper.

    Use of the Digital Object Identifier

    The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
    http://dx.doi.org/10.1016/j.physletb.2010.09.059
    When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

    Proofs

    One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author or a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html.
    If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

    Offprints

    The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.



    You can track your submitted article at http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

Advertisement

advert image